Common-Size Income Statement
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Capital Asset Pricing Model (CAPM)
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Total Asset Turnover since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Cytokinetics Inc., common-size consolidated income statement
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Income statement item | Description | The company |
|---|---|---|
| Operating loss | The net result for the period of deducting operating expenses from operating revenues. | Cytokinetics Inc. operating loss as a percentage of revenues decreased from 2020 to 2021 and from 2021 to 2022. |
| Loss, before income tax provision | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Cytokinetics Inc. loss, before income tax provision as a percentage of revenues decreased from 2020 to 2021 and from 2021 to 2022. |
| Net loss | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Cytokinetics Inc. net loss as a percentage of revenues decreased from 2020 to 2021 and from 2021 to 2022. |